Skip to main content

Table 1 Basic characteristics of total patients with Bronchiolitis Obliterans Syndrome (BOS)

From: Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

Characteristics (N = 61)
Recipient sex, male 33/61 (54.1 %)
Recipient age 46.5 ± 12.3
Donor sex, male 32/59 (54.2 %)
Donor agea 37.1 ± 11.7
Hematologic malignancy
 AML 17 (27.9 %)
 ALL 20 (32.8 %)
 CML 1 (1.6 %)
 NHL 2 (3.3 %)
 MDS 21 (34.4 %)
Donor type
 Unrelated 28 (45.9 %)
 Sibling 25 (41.0 %)
 FMT 8 (13.1 %)
HLA
 full-match 43 (70.5 %)
 mismatch 18 (29.5 %)
Stem cell source
 PB 51 (83.6 %)
 BM 8 (13.1 %)
 Cord 2 (3.3 %)
Time from HSCT to BOS diagnosis, days 434.0 (275.0–835.5)
Acute GVHD 39 (63.9 %)
Chronic GVHD (except lung) 61 (100.0 %)
 Skin 31 (50.8 %)
 Oral 42 (68.9 %)
 Eyes 36 (59.0 %)
 Liver 10 (16.4 %)
 Joint 3 (4.9 %)
Maximal score of chronic GVHD (except lung)b 1 (1–2)
Systemic steroid use 33 (54.1 %)
Steroid dose, mg (equivalent dose of prednisolone) 2.5 (0.0–15.0)
Tacrolimus 18 (29.5 %)
Cyclosporin 9 (14.8 %)
Mycophenolate mofetil 18 (29.5 %)
  1. aAge of two donors were missed because of cord blood transplantation (N = 59). bEach organ was scored as 0, 1, 2 or 3 based on the degree of functional impairment. Data represent the mean ± SD, median (IQR) or n (%). BOS bronchiolitis obliterans syndrome, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic myelogenous leukemia, NHL non-Hodgkin lymphoma, MDS myelodysplastic syndrome, FMT familial-mismatched/haploidentical transplantation, HLA human leukocyte antigen, PB peripheral blood, BM bone marrow, HSCT hematopoietic stem cell transplantation, GVHD graft-versus-host disease